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Abstract 
Chimeric antigen receptors (CARs) are generated by fusing the antigen-binding motif of a 
monoclonal antibody (mAb) with the signal transduction machinery of the T-cell receptor 
(TCR). The genetic modification of T lymphocytes with chimeric receptors specific for tu-
mor-associated antigens (TAAs) allows for the redirection towards tumor cells. Clinical 
experience with CAR-redirected T cells suggests that antitumor efficacy associates with some 
degree of toxicity, especially when TAA expression is shared with healthy tissues. This situ-
ation  closely  resembles  the  case  of  allogeneic  hematopoietic  stem  cell  transplantation 
(HSCT), wherein allorecognition causes both the graft-versus-leukemia (GVL) effect and 
graft-versus-host disease (GVHD). Suicide gene therapy, i.e. the genetic induction of a con-
ditional suicide phenotype into donor T cells, enables dissociating the GVL effect from GVHD. 
Applying suicide gene modification to CAR-redirected T cells may therefore greatly increase 
their safety profile and facilitate their clinical development. 
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Suicide gene therapy and HSCT 
In  HSCT,  the  natural  alloreactivity  of  donor  T 
lymphocytes play a major role in the eradication of 
the  underlying  malignant  disease  in  the  so-called 
GVL effect1. However, the majority of alloantigens are 
not  only  expressed  by  leukemic  cells,  but  also  by 
normal  cells.  The  GVL  effect  is  therefore  often  ac-
companied by an alloimmune attack against healthy 
tissues, whose manifestations are known as GVHD. 
GVHD is a severe disease that is often lethal. GvHD 
prevention is accomplished through either T-cell de-
pletion of the graft or post-transplant immune sup-
pression.  Although effective in abating GVHD inci-
dence and severity, both strategies unfortunately as-
sociate with a significant reduction in the GVL effect, 
thus jeopardizing the overall efficacy of HSCT. 
Alternatively  to  avoiding  alloreactivity 
tout-court,  suicide  gene  therapy  proposes  to  exploit 
the GVL effect, while having the possibility to switch 
off GVHD at will2. This goal is achieved through the 
ex vivo genetic modification of T lymphocytes with a 
suicide gene, i.e. a gene encoding for a factor able to 
convert at a cellular level a non-toxic prodrug into a 
toxic compound. During GVHD, the administration of 
the  prodrug  selectively  eliminates  suicide 
gene-modified  T  cells  without  interfering  with  the 
process  of  immune  reconstitution  operated  by  un-
modified T cells. Suicide gene therapy in the context 
of  HSCT  has  been  pioneered  by  our  group  in  the 
mid-90s with the use of the Herpes simplex thymidine 
kinase  (Hsv-tk)/ganciclovir  (GCV)  suicide  system3. 
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Since then, more than 100 patients have been treated 
worldwide  with  Hsv-tk-modified  T  cells,  demon-
strating that the strategy is safe and efficacious. In-
terestingly, data from phase I/II clinical trials  have 
confirmed earlier studies in humanized mouse mod-
els, which predicted that having GVHD and the GVL 
effect different kinetics and effector mechanisms, the 
therapeutic benefit of HSCT wouldn’t be put at risk by 
the successful activation of the suicide gene machin-
ery4. Moreover, recent improvements in the protocols 
for genetic modification of primary T cells with retro-
viral vectors are expected to further increase the ef-
fectiveness  of  suicide  gene  therapy  with 
Hsv-tk-modified T cells5-7. 
Despite being the first-in-class suicide gene and 
having  clearly  demonstrated  safety  and  efficacy, 
HSV-tk has some limitations8. The first, and most ob-
vious, is that being of viral origin HSV-tk is immuno-
genic and therefore may cause the rejection of modi-
fied T lymphocytes by the immune response of the 
host. The second problem of HSV-tk is its clinical in-
compatibility with the use of GCV for antiviral pur-
poses. HSCT patients often reactivate cytomegalovi-
rus (CMV), which if treated with GCV results in the 
unwanted elimination of modified T cells. The third 
drawback of HSV-tk derives form its mechanism of 
suicide  action.  HSV-tk-modified  T  cells  acquire  the 
ability  to  phosphorilate  GCV,  which  once  incorpo-
rated in the genome causes apoptosis upon cell-cycle 
entry. Therefore, only modified cells that do prolifer-
ate are killed by GCV. 
In order to solve the limitations of HSV-tk, vari-
ous alternative suicide gene systems have been pro-
posed  (see  Table  1).  The  genetic  modification  of  T 
lymphocytes with the B-cell molecule CD209, for ex-
ample, allows their elimination upon administration 
of mAb Rituximab. The major advantage of CD20 as a 
suicide gene is that being of human origin it is not 
expected  to  be  immunogenic.  Moreover,  given  the 
mechanism of action of Rituximab, CD20-modified T 
cells are possibly eliminated regardless of their pro-
liferation  status.  A  possible  pitfall  of  the 
CD20/Rituximab  suicide  gene  system,  however,  re-
lates to the characteristics of the prodrug, given that 
the  biodistribution  of  a  mAb  is  clearly  sub-optimal 
compared to a small molecule such as GCV. In addi-
tion, the administration of Rituximab for the activa-
tion  of  the suicide  gene machinery  will  predictably 
cause the unwanted depletion of normal B cells. Other 
non-immunogenic alternatives to HSV-tk include sui-
cide genes based on the chemical inducers of dimeri-
zation  (CID)10.  According  to  this  technology,  a 
proapototic molecule is adapted to encompass one or 
more binding sites for a CID, which once reaching its 
target(s)  causes  their  oligomerization  with  ensuing 
activation of the apoptotic pathway. In this way, dif-
ferent  apoptotic  pathways  have  been  employed  as 
suicide  systems,  including  the  death  receptor  Fas11 
and the enzyme caspase 912. Beside a very low risk for 
immunogenicity,  these  suicide  genes  share  the  ad-
vantages  of  non  cell-cycle  dependency,  full  clinical 
compatibility and optimal biodistribution, as CID are 
small molecule exquisitely designed for suicide pur-
poses. As a general consideration, however, it has to 
be underlined that at the current state of the art, only 
HSV-tk  has  been  applied  in  humans,  and  that  the 
theoretical  advantages  of  other  suicide  genes  await 
clinical validation. 
 
 
Table 1. Biological characteristics of the different suicide 
genes proposed for use in hematopoietic stem cell trans-
plantation  
  HSV-tk  CD20 ¶  Fas/iCasp9 ¶¶ 
Immunogenicity  +  -  - 
Clinical compatibility  -  -  + 
Cell-cycle dependency  +  -  - 
¶ Clinical incompatibility of CD20 as a suicide gene refers to the 
unwanted elimination of normal B cells upon administration of 
Rituximab for suicide purposes. 
¶¶ Fas is derived from the truncation of the intracellular domain of 
the proapototic molecule Fas and its fusion to CID-binding do-
mains. By analogy, inducible caspase 9 (iCasp9) is derived from the 
fusion of caspase 9 to CID-binding domains. 
 
Suicide gene therapy with CAR-redirected 
T cells 
Adoptive T-cell therapy with CAR-redirected T 
lymphocytes  is  at  the  frontier  of  modern  cancer 
treatment13. The possibility to redirect T cells towards 
virtually any surface TAA by means of gene therapy, 
in fact, opens for the exploitation of the extraordinaire 
therapeutic  potential  of  T  cells  for  an  increasing 
number of patients suffering from cancer. Firstly, pi-
oneered by Zelig Eshhar14, the concept of the genetic 
redirection of T cells by means of a chimeric receptor 
linking the antigen-binding moiety of a mAb in the 
form of a single-chain fragment variable (scFv) region 
to the signal transduction machinery of T cells is now 
being translated into the clinic at an incredible pace. 
Currently, there are a number of active and recruiting 
phase I/II clinical trials aiming at the demonstration 
of the safety and the efficacy of CARs both in the US 
and in the European Union13. The majority of clinical 
trials are focused on lineage marker-specific CARs, that 
is CARs specific for molecules selectively expressed  Journal of Cancer 2011, 2 
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by the malignant counterpart of normal blood cells. 
The most notable examples are CD19-specific CARs, 
which are now being investigated for the treatment of 
different B-cell tumors such as chronic lymphocytic 
leukemia (CLL), acute lymphoid leukemia and lym-
phoma.  Hematological  malignancies,  however,  are 
not the only tumors targeted by CARs. More recently 
a  number  of  novel  oncoantigen-specific CARs,  that  is 
CARs  specific  for  antigens  whose  expression  is 
somewhat linked to the malignant phenotype, have 
been described and have entered the clinical arena for 
some types of solid tumors. 
The appeal of CARs for cancer treatment is mul-
tifaceted  (see  Table  2).  CARs  share  with  mAb  the 
profit of targeting a surface TAA regardless of its na-
ture,  protein,  carbohydrate  or  lipid,  and,  most  im-
portantly, of antigen processing and presentation in 
the context of MHC. Differently from TCR-mediated 
recognition,  CAR-mediated  recognition  is  therefore 
insensitive to tumor escape mechanisms such as an-
tigen processing defects and/or down regulation of 
MHC  expression.  A  logical  consequence  of 
MHC-independent  recognition  is  that  CARs  are 
widely applicable no matter the HLA repertoire of the 
patients.  Apart  from  this,  CAR-redirection  benefits 
from  all  the  advantages  of  tumor  targeting  with  T 
cells, including optimal biodistribution and the ability 
of  persist  long  term,  properties  that  fall  short  with 
mAbs. Moreover, T cells can be complemented with 
genes that enable new properties, such as resistance to 
immunosuppressive  circuits  and,  crucially,  a  condi-
tional suicidal phenotype as in the case of HSV-tk and 
other suicide genes. 
 
Table 2. Schematic comparison of the advantages/ 
disadvantages of mAb, chimeric antigen receptor (CAR)- 
and clonal TCR-redirected T cells for cancer therapy 
  mAb  CAR  TCR 
MHC restriction  -  -  + 
Ag processing  -  -  + 
Persistence  -  +  + 
Biodistribution  -  +  + 
Suicide switch  -  +  + 
 
 
The first clinical experience with CAR-redirected 
T cells was rather disappointing, showing very poor 
in vivo persistence and efficacy. Such a behavior was 
soon linked to the lack of costimulation provided by 
early, or first generation (1G) CARs. Accordingly, the 
provision  of  costimulation  in  trans  via  the  genetic 
modification of T-cell lines specific for latent viruses 
such as Epstein Barr virus proved to ameliorate in vivo 
persistence  and  to  cause  impressive  tumor  regres-
sions15. Alternatively, the progressive addition within 
the CAR backbone of a CD28 costimulatory endodo-
main  (2G  CAR)  has  recently  been  demonstrated  to 
dramatically  increase  in  vivo  persistence16.  On  the 
same line, the implementation of a second costimula-
tory endodomain, either from OX40 or 4-1BB, has also 
been proposed (3G CAR) Unfortunately, along with 
hints of clinical efficacy, 2G and 3G CARs have also 
born  important  safety  concerns,  as  two  serious  ad-
verse events (SAEs) determining the fatal outcome of 
the  treated  patients  were  reported  in  two  distinct 
clinical  trials.  The  first  occurred  in  a  CLL  patient 
treated with T cells redirected with a 2G CAR specific 
for CD19 at the Sloan-Kettering Cancer Center in New 
York17, while the second occurred in a patient with 
colorectal cancer treated T cells redirected with a 2G 
CAR  specific  for  CD19  at  the  National  Institute  of 
Health in Bethesda18. In the first case, the SAE was 
later  recognized  as  a  tumor-lysis  syndrome,  and 
therefore  not  primarily  related  to  the  biology  of 
CAR-redirected T cells. In the second case, however, 
the SAE was likely to be directly caused by excessive 
cytokine  release  upon  on-target  recognition,  which 
possibly included also lung epithelia expressing low 
levels of HER2/neu. 
The  association  between  clinical  efficacy  and 
toxicity  when  applying  CAR-redirected  T  cells  for 
cancer treatment much resembles the case of HSCT, 
wherein the GVL effect and GVHD are tightly linked 
phenomenons. Since suicide gene therapy for HSCT 
has  demonstrated  the  potential  to  operate  a  mean-
ingful  dissociation  between  the  GVL  effect  and 
GVHD, it is reasonable to think that the implementa-
tion of a suicide gene in CAR-redirected T cells may 
help  mitigating  their  risks,  while  preserving  their 
therapeutic effect. The use of a suicide gene may be 
particularly appropriate when targeting oncoantigens 
whose expression is leaky and therefore present, al-
beit at lower levels, on healthy tissues. Due to previ-
ous experience with CAR-redirected T cells, it is un-
likely that suicide genes would work as a universal 
surrogate for safety. For example, by no means, sui-
cide genes may substitute from a correct clinical de-
velopment plan, including the cautious choice of the 
starting dose when applying a specific CAR for the 
first time in humans or a careful intra- or inter-patient 
dose escalation to avoid early or idiosynchrasic toxici-
ties19.  None  withstanding  this,  suicide  genes  may 
prove  greatly  helpful  in  managing  intermediate  and 
late toxicities not only during the different phases of 
clinical development, but especially, and hopefully, in 
the case CAR-redirected T cells would finally translate 
into mainstream medicine.  Journal of Cancer 2011, 2 
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Figure 1. Schematic representation of the different generations of CARs (1G, first generation, 2G, second generation, 3G, 
third generation). The scFv is highlighted in green, while the different component of TCR signal transduction machinery are 
highlighted in red (CD3  chain/ZAP70), blue (CD28/PI3K) and yellow (4-1BB or OX40/TRAF). 
 
 
Conflict of Interest 
The authors have declared that no conflict of in-
terest exists. 
References 
1.  Appelbaum FR. Haematopoietic cell transplantation as immu-
notherapy. Nature. 2001;411(6835):385-389. 
2.  Bondanza A, Ciceri F, Bonini C. Application of donor lympho-
cytes expressing a suicide gene for early GVL induction and 
later control of GVH reactions after bone-marrow transplanta-
tion. Methods Mol Med. 2005;109:475-486. 
3.  Bonini C, Ferrari G, Verzeletti S, et al. HSV-TK gene transfer 
into  donor  lymphocytes  for  control  of  allogeneic 
graft-versus-leukemia. Science. 1997;276(5319):1719-1724. 
4.  Ciceri  F,  Bonini  C,  Marktel  S,  et  al.  Antitumor  effects  of 
HSV-TK-engineered  donor  lymphocytes  after  allogeneic 
stem-cell transplantation. Blood. 2007;109(11):4698-4707. 
5.  Bondanza A, Valtolina V, Magnani Z, et al. Suicide gene ther-
apy  of  graft-versus-host  disease  induced  by  central  memory 
human T lymphocytes. Blood. 2006;107(5):1828-1836. 
6.  Kaneko S, Mastaglio S, Bondanza A, et al. IL-7 and IL-15 allow 
the  generation  of  suicide  gene-modified  alloreactive 
self-renewing  central  memory  human  T  lymphocytes.  Blood. 
2009;113(5):1006-1015. 
7.  Bondanza A, Hambach L, Aghai Z, et al. IL-7 receptor expres-
sion identifies suicide gene-modified allospecific CD8+ T cells 
capable  of  self-renewal  and  differentiation  into  antileukemia 
effectors. Blood. 2011; Epub. 
8.  Lupo-Stanghellini MT, Provasi E, Bondanza A, Ciceri F, Bor-
dignon C, Bonini C. Clinical impact of suicide gene therapy in 
allogeneic hematopoietic stem cell transplantation.  Hum Gene 
Ther. 2010;21(3):241-250. 
9.  Introna M, Barbui AM, Bambacioni F, et al. Genetic modifica-
tion of human T cells with CD20: a strategy to purify and lyse 
transduced  cells  with  anti-CD20  antibodies.  Hum  Gene  Ther. 
2000;11(4):611-620. 
10.  Rollins CT, Rivera VM, Woolfson DN, et al. A ligand-reversible 
dimerization  system  for  controlling  protein-protein  interac-
tions. Proc Natl Acad Sci U S A. 2000;97(13):7096-7101. 
11.  Thomis  DC,  Marktel  S,  Bonini  C,  et  al.  A  Fas-based  suicide 
switch in human T cells for the treatment of graft-versus-host 
disease. Blood. 2001;97(5):1249-1257. 
12.  Straathof KC, Pule MA, Yotnda P, et al. An inducible caspase 9 
safety switch for T-cell therapy. Blood. 2005;105(11):4247-4254. 
13.  Jena  B,  Dotti  G,  Cooper  LJ.  Redirecting  T-cell  specificity  by 
introducing a tumor-specific chimeric antigen receptor. Blood. 
2011;116(7):1035-1044. 
14.  Gross  G,  Waks  T,  Eshhar  Z.  Expression  of  immunoglobu-
lin-T-cell  receptor  chimeric  molecules as  functional  receptors 
with  antibody-type  specificity.  Proc  Natl  Acad  Sci  U  S  A. 
1989;86(24):10024-10028. 
15.  Pule  MA,  Savoldo  B,  Myers  GD,  et  al.  Virus-specific  T  cells 
engineered  to  coexpress  tumor-specific  receptors:  persistence 
and antitumor activity in individuals with neuroblastoma. Nat 
Med. 2008;14(11):1264-1270. 
16.  Savoldo  B,  Ramos  CA,  Liu  E,  et  al.  CD28  costimulation  im-
proves  expansion  and  persistence  of  chimeric  antigen  recep-
tor-modified  T  cells  in  lymphoma  patients.  J  Clin  Invest. 
2011;121(5):1822-1826. 
17.  Brentjens R, Yeh R, Bernal Y, Riviere I, Sadelain M. Treatment 
of chronic lymphocytic leukemia with genetically targeted au-
tologous T cells: case report of an unforeseen adverse event in a 
phase I clinical trial. Mol Ther. 2010;18(4):666-668.  Journal of Cancer 2011, 2 
 
http://www.jcancer.org 
382 
18.  Morgan RA, Yang JC, Kitano M, Dudley ME, Laurencot CM, 
Rosenberg SA. Case report of a serious adverse event following 
the administration of T cells transduced with a chimeric antigen 
receptor recognizing ERBB2. Mol Ther. 2010;18(4):843-851. 
19.  Ertl  HC,  Zaia  J,  Rosenberg  SA,  et  al.  Considerations  for  the 
Clinical  Application  of  Chimeric  Antigen  Receptor  T  Cells: 
Observations from a Recombinant DNA Advisory Committee 
Symposium  Held  June  15,  2010.  Cancer  Res. 
2011;71(9):3175-3181.  